Combination Therapy with Pparα and Pparγ Agonists in Type 2 Diabetes Blunts the Reduction in Intra-Organ Triglyceride Content Seen with Pparγ Monotherapy.Published in:Diabetes, 2007, v. 56, p. A163By:Balasubramanian, Ravikumar;Gerrard, Jean;English, Philip T.;Firbank, Michael F.;Taylor, RoyPublication type:Article